July 14, 2006 – Forest Labs moved substantially higher after winning a patent suit that protects Lexapro from a Teva generic equivalent; CuraGen began a Phase I/II trial of PXD101 for liver cancer; Avid will collaborate with Schering to develop new imaging agents to provide a definitive diagnosis for Alzheimer’s disease; deCODE genetics fell after selling a new $30 million of issue of common stock; a hepatitis B drug from Nabi Biopharma was recommended for approval by an FDA scientific advisory committee; ConjuChem put its HIV drug on clinical hold after the death of a patient in a clinical trial. The Centient Biotech 200™ fell 48 points to 3522, a drop of 1.34%. More details...
